Soliten (Vesicare) 5mg – 30 tablet

USD $60.54

Each Soliten contains 5 mg Solifenacin with 30 tablets used for the treatment of an overactive bladder by relaxing the muscles of the urinary tract

ATC Classification: G04BD08
Active Ingrediant: Solifenacin
Generic Name: Soliten
Manufacturer: Ranbaxy Limited
Strength: 5mg
Dosage Type: Tablet
Packaging Type: Blister in Box
Contains: 30 Tab

Examples of Packages sent


Medication Safety Issues

Sound-alike/look-alike issues:

VESIcare may be confused with Vesanoid, Vessel Care (nutritional supplement)

Geriatric Patients: High-Risk Medication:

Beers Criteria: Solifenacin is identified in the Beers Criteria as a potentially inappropriate medication in patients 65 years and older due to its strong anticholinergic properties (Beers Criteria [AGS 2019]).



Store at 25?C (77?F); excursions permitted to 15?C to 30?C (59?F to 86?F).


Adverse Reactions

>10%: Gastrointestinal: Xerostomia (11% to 28%), constipation (5% to 13%)

1% to 10%:

Cardiovascular: Hypertension (1%), lower extremity edema (1%)

Central nervous system: Fatigue (2%), depression (1%)

Gastrointestinal: Dyspepsia (4%), nausea (3%), upper abdominal pain (2%), vomiting (1%)

Genitourinary: Urinary tract infection (5%), urinary retention (1%)

Ophthalmic: Blurred vision (4% to 5%), dry eye syndrome (2%)

Respiratory: Cough (1%)

Miscellaneous: Influenza (2%)

<1%, postmarketing, and/or case reports: Abnormal hepatic function tests, anaphylaxis, angioedema, atrial fibrillation, confusion, decreased appetite, delirium, drowsiness, dry nose, dysgeusia, erythema multiforme, exfoliative dermatitis, fecal impaction, gastroesophageal reflux disease, gastrointestinal obstruction, glaucoma, hallucination, headache, hyperkalemia, hypersensitivity reaction, myastheni

Additional information

Active Ingrediant

Generic Name

Alternate Names

, , , , , , , , , , , , , , , ,


Dosage Type

Packaging Type




There are no reviews yet.

Be the first to review “Soliten (Vesicare) 5mg – 30 tablet”

Your email address will not be published. Required fields are marked *